



(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 14/705 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2021/029138

(22) International Filing Date:

26 April 2021 (26.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/015,362 24 April 2020 (24.04.2020) US
63/073,133 01 September 2020 (01.09.2020) US

(71) Applicants: **MEMORIAL SLOAN-KETTERING CANCER CENTER** [US/US]; 1275 York Avenue, New York, NY 10065 (US). **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(72) Inventors: **FEUCHT, Judith**; Corrensstrasse 53, 72076 Tuebingen (DE). **MANSILLA-SOTO, Jorge**; 72-72 112th Street Apt. 3A, Forest Hills, NY 11375 (US). **RIVIERE, Isabelle**; 15 West 84th Street, Apt. 2C, New York, NY 10024 (US). **SADELAIN, Michel**; 15 West 84th Street, Apt. 2C, New York, NY 10024 (US). **VINCENT, Loic**; 40 Lands-

downe Street, Cambridge, MA 02139 (US). **SHAPIRO, Gary**; 40 Landsdowne Street, Cambridge, MA 02139 (US). **NG, Mei Rosa**; 40 Landsdowne Street, Cambridge, MA 02139 (US). **TAVARES, Dan**; 40 Landsdowne Street, Cambridge, MA 02139 (US). **HE, Xingyue**; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(74) Agent: **SONG, Amy Yang et al.**; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND USE THEREOF




FIG. 1A

(57) Abstract: The presently disclosed subject matter provides chimeric antigen receptors (CARs) that specifically target CD 19 and cells comprising such CD19-targeted CARs. The presently disclosed subject matter further provides uses of the CD19-targeted CARs for treatment, e.g., for treating blood cancer.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

02 December 2021 (02.12.2021)